The invention relates to an I<131> labeled anti-human
neuropilin receptor-2 (NRP-2)
monoclonal antibody E4. The
antibody E4 is labeled by I<131> through a
chloramine T labeling method. The I<131>-E4 is produced through the following steps: 1) preparing the
antibody E4, NaI<131>, and PBS being 7.4-7.6 in pH value, and adding the components into an EP tube, adding newly-prepared
chloramine T and rapidly vibrating and uniformly mixing the liquid, performing a reaction at
room temperature, and adding a newly-prepared reduction agent,
sodium metabisulfite, to terminate the
iodination reaction; 2) moving out the reaction liquid, and measuring the labeling rate of a labeled product through TLC, normal
saline being a developing
solvent; 3) treating the reaction liquid on a
Sephadex G25 column to purify the reaction liquid with PBS being about 7.4 in pH value as an eluting solution to prepare I<131>-E4. Advantages of the
radionuclide are integrated with the antitumor
cell humanized
monoclonal antibody, so that the targeting property and
molecular imaging effect of the
medicine are improved. The antibody E4 can increase the early-stage diagnosis rate and monitor
treatment effect of positive tumor expressed by the NRP-2, has a wider available range and is suitable for imaging positive tumors expressed by the NRP-2 in all stages.